$655 Million is the total value of Darwin Global Management, Ltd.'s 13 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | New | PFIZER INC | $454,553,000 | – | 7,697,762 | +100.0% | 69.44% | – |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $71,605,000 | -29.0% | 605,587 | -19.5% | 10.94% | -41.1% |
| AZN | New | ASTRAZENECA PLCsponsored adr | $29,819,000 | – | 511,908 | +100.0% | 4.56% | – |
| INBX | Buy | INHIBRX INC | $25,852,000 | +43.0% | 591,975 | +9.1% | 3.95% | +18.7% |
| BNTX | Sell | BIONTECH SEsponsored ads | $23,217,000 | -36.0% | 90,057 | -32.3% | 3.55% | -46.9% |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $12,428,000 | – | 166,190 | +100.0% | 1.90% | – |
| FATE | Sell | FATE THERAPEUTICS INC | $8,983,000 | -57.1% | 153,537 | -56.5% | 1.37% | -64.4% |
| KROS | New | KEROS THERAPEUTICS INC | $6,524,000 | – | 111,500 | +100.0% | 1.00% | – |
| VIR | Buy | VIR BIOTECHNOLOGY INC | $6,106,000 | +209.6% | 145,841 | +221.9% | 0.93% | +157.0% |
| CCXI | New | CHEMOCENTRYX INC | $5,891,000 | – | 161,802 | +100.0% | 0.90% | – |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $5,615,000 | +485.5% | 317,428 | +833.7% | 0.86% | +384.7% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $3,143,000 | +9.6% | 216,143 | +35.6% | 0.48% | -9.1% |
| VERV | Sell | VERVE THERAPEUTICS INC | $852,000 | -33.9% | 23,104 | -15.7% | 0.13% | -45.1% |
| AVTE | Exit | AEROVATE THERAPEUTICS INC | $0 | – | -12,484 | -100.0% | -0.05% | – |
| Exit | ADAGIO THERAPEUTICS INC | $0 | – | -86,528 | -100.0% | -0.67% | – | |
| BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -253,692 | -100.0% | -2.19% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -2,000,000 | -100.0% | -63.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
| KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
| INHIBRX INC | 5 | Q4 2021 | 3.9% |
| ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
| AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
| ARGENX SE | 4 | Q3 2023 | 70.2% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
| FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
| ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
| INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-28 |
| SC 13D/A | 2023-06-28 |
| SC 13D/A | 2023-05-25 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-03 |
| 3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.